

**GF/B45/EDP22: Decision on the Secretariat’s Recommendation on Additional Funding for the 2020-2022 Allocation Period**

The Board:

1. Approves the revised budget recommended for the grant listed in Table 2 of GF/B45/ER19 (“Table 2”);
2. Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and
3. Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.

This decision does not have material budgetary implications for operating expenses.

**Table 2: Secretariat’s Recommendation on Additional Funding to be Integrated into Grants**

<b>N</b>	<b>Applicant</b>	<b>Disease Component</b>	<b>Grant Name</b>	<b>Additional Funding Source</b>	<b>Currency</b>	<b>Previous Approved Grant Budget</b>	<b>Additional Funds</b>	<b>Revised Grant Budget for approval</b>	<b>Rationale</b>
1	<a href="#">Bangladesh</a>	Malaria	BGD-M-BRAC	Private Sector: Comic Relief Inc.	US\$	12,951,846	1,170,015	14,121,861	This additional funding from Comic Relief Inc. will be invested in service delivery and in-country distribution activities.
2	<a href="#">Indonesia</a>	Tuberculosis	IDN-T-MOH	Debt2Health Swap Agreement	US\$	131,267,438	38,466,058	169,733,496	This additional funding sourced through a Debt2Health swap agreement between Germany and Indonesia (signed in April 2021) will fill critical TB gaps, including to mitigate the severe impact of COVID-19 on the national TB response.
3			IDN-T-PBSTPI		US\$	26,461,010	20,792,991	47,254,001	